A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma
N
Nabil Adra, MD
Primary Investigator
Overview
The purpose of this study is to evaluate the clinical activity of sitravatinib in combination with nivolumab in patients with advanced or metastatic urothelial carcinoma.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Urothelial Carcinoma
-
Age: Between 18 Years - 100 Years
-
Gender: All
Inclusion Criteria
- Diagnosis of urothelial carcinoma
For a full list of participation criteria, please visit clinicaltrials.gov.
Updated on
19 Apr 2024.
Study ID: 1902515462 (516-003)
